Hallym University Chuncheon Sacred Heart Hospital (President Lee Jae-jun) anunció el 29th that it recently firmó un memorandum of understanding (MOU) with the Hallym University Medical Bio Convergence Research Institute, IonCell Co., Ltd. (CEO Kim Hyung-soo), and RudaCure Inc. (CEO Yongho Kim) for investigación conjunta on CAR-T and ADC drugs.
This MOU fue establecido para integrate the core technologies and capabilities of each institution in order to develop effective therapeutics and, further, to contribute to the advancement of the medical bio industria at both the regional and national levels.
The specific terms of the acuerdo include: 1) mutual sharing of expertise and tecnología between the instituciones; 2) desarrollo conjunto of CAR-T and ADC drugs; and 3) provision of innovador tratamientos and therapies to pacientes. A través de esto acuerdo, the core technologies and infrastructure of each institution—including the excellent clinical data held by Hallym University Chuncheon Sacred Heart Hospital, the drug screening tecnología of IonCell Co., Ltd., and the drug eficacia evaluación and therapeutic desarrollo tecnología of RudaCure Inc.—are esperado to generate synergies. The investigación conjunta will aim to develop therapeutics utilizing Chimeric Antigen Receptor T-cell (CAR-T) tecnología and tratamientos based on Antibody-Drug Conjugates (ADC), referred to as a next-generation cancer tratamiento tecnología.
* Sources
[Edaily] https://www.edaily.co.kr/news/read?newsId=01449766635843440&mediaCodeNo=257
[Uigye Sinmun] https://www.medworld.co.kr/news/articleView.html?idxno=227581